← Human Trials & Peer-Reviewed Studies
Characterization of angiotensin-II effects on cerebral and ocular circulation by noninvasive methods
Plain-language guide to PMID 9159565 (1997): double-blind randomized controlled trial study of Angiotensin II in 10 subjects.
Key Facts
- PMID
- 9159565
- Journal
- British journal of clinical pharmacology
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Krejcy K et al. (7 authors)
- DOI
- 10.1046/j.1365-2125.1997.00585.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as a randomized controlled trial.
The role of the renin-angiotensin-system (RAS) in the cerebral and ocular circulation is still a matter of controversy.
In vitro and animal data lead to partially contradicting results.
However, direct investigation of locally generated angiotensin II (Ang II) in humans is not possible in vivo.
Who Took Part
According to the abstract, 10 subjects were involved.
PubMed indexes the participants as adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The subjects were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.
Neither the subjects nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.
Blood flow velocities were assessed by Doppler sonography, fundus pulsation amplitudes (FPA), which estimate local pulsatile ocular blood flow were measured by laser interferometry.
Additionally, systemic blood pressure and pulse rate were measured.
What Was Measured
PubMed files the paper under topics including Angiotensin II, Blood Pressure, Cerebral Arteries, Cerebrovascular Circulation, Eye, Fundus Oculi and Ophthalmic Artery.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 10 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1997 (British journal of clinical pharmacology), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.